Journal of Tissue Repair and Regeneration

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Tissue Repair and Regeneration -antibody engineering-WEI LI

China

NIH/NCI/CIP/LEI

301-846-6275

Send an Email

WEI LI

Address:

Protein Interactions Group,
Cancer and Inflammation Program,
Center for Cancer Research,
National Cancer Institute,
National Institutes of Health,
1050 Boyles Street,
Building 567 Room 180,
Frederick, MD 21702.

Research Interests:

  • antibody engineering
  • vaccine development
  • cancer immunotherapy

Biography:

  • Li Wei received his bachelor degree of applied chemistry in 2009 from Huazhong University of Science and Technology, China.
  • Trained as a bioinorganic chemist in Institute of Biomedical Science (IBS), he earned his PhD in chemical biology from Fudan University, China in 2014.
  • His PhD work focus on dissecting the underlying mechanisms of metalloproteins and metalloenzymes involved in key physiological and pathological bio-processes, which include redox-tuning metalloenzymes, metal ions homeostasis maintaining regulators and metalloproteins in neurodegenerative disease.
  • In 2014, He joined Dr. Dimiter Dimitrov's group at National Cancer Institute, National Institutes of Health, U.S.A (NIH/NCI) for his postdoctoral training where he study on antibody engineering and vaccine development using combinations of methodologies involving display/screening/library, protein biochemistry, structural biology and computational biology as well as virology, immunology.
  • His research field covers the development of useful antibody therapeutics and vaccines against cancer, HIV-1 and emerging and biodefense-related viruses; T Cell Receptor (TCR) engineering to targeting tumor associated antigens or specific antigens; Chimeric Antigen receptor (CAR) engineering; and bispecific antibody design and development.